Last reviewed · How we verify
Placebo of intravenous L-citrulline — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo of intravenous L-citrulline (Placebo of intravenous L-citrulline) — Asklepion Pharmaceuticals, LLC. This is a placebo control (inert substance) used in clinical trials to compare against active intravenous L-citrulline treatment.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo of intravenous L-citrulline TARGET | Placebo of intravenous L-citrulline | Asklepion Pharmaceuticals, LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo of intravenous L-citrulline CI watch — RSS
- Placebo of intravenous L-citrulline CI watch — Atom
- Placebo of intravenous L-citrulline CI watch — JSON
- Placebo of intravenous L-citrulline alone — RSS
Cite this brief
Drug Landscape (2026). Placebo of intravenous L-citrulline — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-of-intravenous-l-citrulline. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab